Mayo Clinic Laboratory and Pathology Research Roundup: Oct. 24

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.


Featured Abstract

New Developments in Clinical Bacteriology Laboratories

carbapenem-resistant-Enterobacteriaceae-16-x-9There are a number of changes underway in modern clinical bacteriology laboratories. Panel-based molecular diagnostics are now available for numerous applications, including, but not limited to, detection of bacteria and select antibacterial resistance markers in positive blood culture bottles, detection of acute gastroenteritis pathogens in stool, and detection of selected causes of acute meningitis and encephalitis in the cerebrospinal fluid. Today, rapid point-of-care nucleic acid amplification tests are bringing the accuracy of sophisticated molecular diagnostics closer to patients. A proteomic technology, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, is enabling rapid, accurate, and cost-effective identification of bacteria, as well as fungi, recovered in cultures. Laboratory automation, common in chemistry laboratories, is now available for clinical bacteriology laboratories. Finally, there are several technologies under development, such as rapid phenotypic antimicrobial susceptibility testing, whole-genome sequencing, and metagenomic analysis for the detection of bacteria in clinical specimens. The paper was published in Mayo Clinic Proceedings

Ruling in Myocardial Injury and Ruling out Myocardial Infarction with the European Society of Cardiology 1-Hour Algorithm

cardio-960x540High sensitivity cardiac troponin (hscTn) assays are used everywhere except in the United States. One potential advantage of these assays is the ability to triage patients with possible ischemia more rapidly and, there is an understandable desire to find easy, facile algorithms to do this. Mayo Clinic researchers took this approach with hscTn in the evaluation of patients with possible acute myocardial infarction (AMI) using an algorithm developed by the Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) trial. Intrinsic to it is the concept that both ruling-out and ruling-in AMI rapidly (within one hour) is based on initially low concentrations or small changes over the first hour for ruling out and the use of larger changes and fixed cut off concentrations for ruling in. Unfortunately, the validation of this algorithm has often left a good deal to be desired. Despite that fact, it was incorporated into the European Society of Cardiology guidelines. The study was published in Circulation


Published to PubMed This Week

kschrib

Kelley Schreiber

Kelley Schreiber is a Marketing Channel Manager at Mayo Medical Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her new kitten, and exploring new foods.